Related by context. All words. (Click for frequent words.) 89 clinical trial 79 Phase III trials 79 Phase III clinical trials 73 Phase III clinical 72 preclinical 71 clinical 71 Clinical trials 70 Phase IIb trial 69 preclinical studies 68 Phase IIb 68 Phase 2b study 67 phase IIa 67 Phase IIa trial 67 Phase III 67 phase IIb 67 phase IIb clinical 66 Phase 2b trial 66 Phase IIb clinical trials 66 midstage studies 66 clinical pharmacology studies 66 randomized clinical trials 66 phase IIa clinical 66 Phase 2b clinical 65 Phase Ib 65 Phase IIb clinical 65 Phase IIb trials 65 midstage trials 65 Phase Ib clinical 64 Phase Ib clinical trials 64 Phase IIa trials 64 Phase 2a trial 64 tremelimumab 64 pivotal Phase III 63 Phase IIa clinical 63 Phase IIa clinical trials 63 randomized trials 63 Phase IIIb clinical 63 tolevamer 63 nonclinical studies 63 Phase #b/#a 63 midstage clinical trials 63 Phase 1b trial 63 investigational 63 Dacogen injection 63 phase IIb trial 63 PREOS 63 Phase IIa 62 dirucotide 62 JAK inhibitor 62 confirmatory Phase III 62 Clinical Trial 62 GLP toxicology studies 62 Phase 2a clinical 62 Asentar 62 multicenter Phase II 62 Phase IIIb study 62 efficacy 62 OvaRex ® MAb 61 randomized controlled clinical trials 61 teduglutide 61 Myocet 61 Allovectin 7 61 trastuzumab DM1 61 randomized clinical 61 placebo controlled trials 61 multicenter trials 61 phase Ib 61 KRN# 61 OHR/AVR# 61 Civacir 61 Phase 1b clinical 61 OvaRex R 61 Phase 2b clinical trials 61 Lupuzor 61 IND enabling 61 Factor VIIa 61 Phase IIIb 61 TELINTRA 61 Allovectin 7 R 61 Phase Ib study 61 IND submission 61 PEG PAL 61 pharmacokinetic studies 61 IL# PE#QQR 61 bardoxolone 61 Viprinex 61 placebo controlled clinical 60 liprotamase 60 Exherin TM 60 preclinical toxicology 60 Phase 2a clinical trials 60 valopicitabine 60 isavuconazole 60 bioequivalence studies 60 PSN# [002] 60 cannabinor 60 rALLy trial 60 Corlux 60 GSK# [002] 60 Fodosine 60 postapproval 60 Aryplase 60 mipomersen 60 Phase Ia 60 talactoferrin 60 multicenter clinical 60 IIa trial 60 Urocidin 60 oral deforolimus 60 TELCYTA 60 Cintredekin Besudotox 60 MBP# [001] 60 budesonide foam 60 Sutent sunitinib 60 Phase 2b 60 Hepatocellular Carcinoma HCC 60 TQT studies 60 #D#C# 60 multicenter Phase 60 AzaSite Plus 59 dirucotide MBP# 59 Sulonex 59 INCB# [001] 59 multicenter clinical trials 59 pivotal bioequivalence 59 DXL# 59 CDP# 59 Prednisporin TM 59 OncoVEX GM CSF 59 midstage clinical 59 RhuDex 59 registrational 59 Sebivo 59 ganetespib 59 GALNS 59 axitinib 59 phase IIb study 59 Mipomersen 59 Phase IIB 59 TOCOSOL Paclitaxel 59 HGS# 59 placebo controlled studies 59 placebo controlled clinical trials 59 Memryte 59 AQ4N 59 alogliptin 59 FOLOTYN ® 59 Phase 2a 59 COMFORT II 59 ruxolitinib 59 personalized immunotherapy 59 TLK# 59 vemurafenib 59 eprotirome 59 iii GTx 59 MyVax 59 ProLindac 59 cancer immunotherapies 59 ganaxolone 59 IIa clinical 59 ENRICH trial 59 Omigard 59 Amrubicin 59 bicifadine 59 anidulafungin 59 pharmacokinetic 59 HspE7 59 Phenoptin 59 bioabsorbable stent 59 MAXY alpha 59 Allovectin 7 ® 59 trastuzumab DM1 T DM1 59 pharmacokinetic PK study 59 forodesine 59 Phase #b/#a trial 59 HuMax CD# 59 Proellex TM 59 RSD# oral 59 Diamyd ® 58 faropenem 58 Phase III Clinical Trials 58 ocrelizumab 58 bioequivalence 58 Investigational 58 olaparib 58 betrixaban 58 HuMax CD4 58 Amigal 58 preclinical efficacy 58 ReN# 58 investigational drug 58 Solazed 58 Icatibant 58 LEP ETU 58 tivozanib 58 pitavastatin 58 AZILECT R 58 BrachySil 58 PEARL SC 58 PANVAC VF 58 double blinded placebo 58 SNT MC# 58 LEUKINE 58 cangrelor 58 elotuzumab 58 BLA filing 58 afamelanotide 58 ATryn ® 58 EOquin 58 CoFactor 58 clinicaltrials 58 dose escalation 58 Cogane 58 CRD5 58 Panzem 58 adipiplon 58 albiglutide 58 ADVANCE PD 58 dose escalation trial 58 investigational therapies 58 Linjeta TM 58 dalbavancin 58 integrase inhibitor 58 Trofex 58 Clinical Trials 58 YONDELIS 58 Zolinza 58 torezolid phosphate 58 Phase #/#a 58 Menerba 58 INDs 58 NEUMUNE 58 Prodarsan ® 58 CRLX# 58 phase 2a 58 vosaroxin 58 HCV SPRINT 58 clevudine 58 confirmatory clinical 58 RhuDex ® 58 ALTU 58 vismodegib 58 alvespimycin 58 Chrysalin 58 TBC# 58 cardio renal 58 AZILECT ® 58 SEPET TM 58 Mepact 58 ProSavin 58 Nasulin 58 phase Ib clinical 58 Fx #A 58 riociguat 58 AEG# 58 KNS # 58 MOZOBIL 58 FM VP4 58 oral taxane 57 IIa clinical trials 57 DR Cysteamine 57 Canvaxin 57 Cloretazine ® 57 alvimopan 57 Phase III pivotal 57 SYMMETRY trial 57 Medidur TM FA 57 oral methylnaltrexone 57 multicenter study 57 HPTN 57 L BLP# 57 sorafenib Nexavar 57 pertuzumab 57 Phase Ib II 57 AEGR 57 Desmoteplase 57 non alcoholic steatohepatitis 57 SinuNase TM 57 Anthim 57 HCV protease inhibitors 57 topical formulations 57 Phase 1b 57 HQK 57 dose escalation Phase 57 ABSORB trial 57 Atrasentan 57 IMA# 57 randomized Phase 57 Phase III randomized controlled 57 Onalta ™ 57 Excellagen 57 NP2 Enkephalin 57 rhThrombin 57 registrational trial 57 Cardio Vascu Grow 57 ORENCIA R 57 Abiraterone 57 DPP4 inhibitor 57 Personalized Immunotherapy 57 TKM ApoB 57 Advexin 57 GVAX 57 randomized controlled 57 peginesatide 57 PrevOnco 57 LibiGel Phase III 57 Cloretazine 57 Stimuvax R 57 methylnaltrexone 57 Virulizin R 57 Proxinium TM 57 bioequivalency 57 EFAPROXYN 57 Zensana 57 mertansine 57 Plenaxis TM 57 OncoVex 57 including eniluracil ADH 57 Zybrestat 57 Velcade bortezomib 57 Zavesca R 57 SUTENT ® 57 ZFP Therapeutic 57 visilizumab 57 crizotinib 57 SILENOR 57 Aurora kinase inhibitor 57 figitumumab 57 ToGA 57 ixabepilone 57 Zalbin 57 Bronchitol 57 nimotuzumab 57 tafamidis 57 dose escalation study 57 Insegia 57 Adentri 57 PXD# 57 daclizumab 57 motesanib 57 MAGE A3 ASCI 57 tanespimycin 57 GTC recombinant human 57 neratinib 57 BLA submission 57 Nexavar sorafenib 57 severe hypercholesterolemia 57 pivotal Phase 57 rALLy clinical trial 57 CEQ# 57 ITAX 57 prostone 57 PREOS R 57 deforolimus 57 BRIM3 57 etanercept Enbrel 57 European Sepsis Trial 57 arzoxifene 57 antisense drug 57 Soliris TM eculizumab 57 tramiprosate Alzhemed TM 57 picoplatin 57 crofelemer 57 placebo controlled Phase 57 randomized Phase IIb 57 postmarketing surveillance 57 Heplisav 57 lomitapide 57 Hyphanox 57 ELACYT 57 atrasentan 57 Pivotal Trial 57 BrachySil TM 57 CytoFabTM 57 Cethromycin 57 Emselex 57 preclinically 57 Xinlay 57 VITAL Trial 57 ASA# 57 Voraxaze ™ 57 oral ridaforolimus 57 ataluren 57 UPLYSO 57 Cutanea 57 MAXY VII 57 non nucleoside HCV 57 EOquin TM 57 ALN TTR# 57 JAK2 inhibitor 57 TACI Ig 57 Dalbavancin 57 PROPEL trial 56 GLPG# 56 Phase III psoriasis 56 BRAF inhibitor 56 celgosivir 56 gefitinib Iressa 56 MEK inhibitors 56 enzastaurin 56 TYZEKA 56 Syncria 56 ADAGIO study 56 Cleviprex TM clevidipine 56 LY# [003] 56 CINTREDEKIN BESUDOTOX 56 SUCCEED trial 56 QLT# 56 SARMs 56 Rasagiline 56 Arranon 56 Aphthasol R 56 therapeutic regimens 56 Azilect ® 56 Trizytek 56 ThGRF 56 Pazopanib 56 Phase 1a 56 multicenter 56 dacetuzumab 56 LBH# 56 Fabry Disease 56 IIa clinical trial 56 Urocortin 2 56 NO# [002] 56 SUTENT 56 dexanabinol 56 Plicera 56 triphendiol 56 phase IIb III 56 randomized multicenter Phase III 56 MyVax R 56 Acapodene 56 MYDICAR 56 Neulasta ® 56 panitumumab Vectibix 56 Azedra 56 phase IIIb 56 Onconase 56 Ixempra 56 Relovair 56 cediranib 56 Tolamba 56 GRN# 56 entinostat 56 masitinib 56 placebo controlled Phase III 56 dexpramipexole 56 PROSTVAC TM 56 Ereska 56 Triolex 56 teriflunomide 56 NABTT 56 StemEx R 56 reslizumab 56 ancrod 56 Triapine R 56 eniluracil 56 eltrombopag 56 ASONEP 56 obatoclax 56 Mylotarg 56 blood clot dissolver 56 Phase III Clinical Trial 56 torcetrapib atorvastatin 56 Rotarix ® 56 INTERCEPT platelets 56 Serdaxin 56 LibiGel ® 56 sodium thiosulfate STS 56 depsipeptide 56 Trimesta 56 therapies 56 AERx iDMS 56 Vivecon 56 randomized controlled trials 56 Phase IIb III 56 GAMMAGARD 56 pradefovir 56 AVN# [001] 56 Egrifta 56 PLK1 SNALP 56 glufosfamide 56 almorexant 56 midstage clinical trial 56 Rezular 56 APD# 56 Xyotax 56 Zavesca r 56 R#/MEM # 56 AeroLEF TM 56 OncoVEX 56 metastatic RCC 56 HGS ETR1 56 cintredekin besudotox 56 GSK # 56 Alzhemed TM 56 Clinical Study 56 EndoTAG TM -1 56 Vectibix panitumumab 56 BCX# 56 ceftobiprole 56 elacytarabine 56 BNC# 56 cathepsin K inhibitor 56 Neurostep TM 56 investigational compounds 56 ularitide 56 MyVax personalized immunotherapy 56 targeted radiotherapeutic 56 HCV polymerase inhibitor 56 Flutiform TM 56 Pimavanserin 56 therapeutic monoclonal antibody 56 TaiGen 56 CB2 selective receptor agonist 56 pegloticase 56 Onbrez Breezhaler 56 Augment Injectable 56 Ceflatonin R 56 Safinamide 56 sunitinib 56 PDE4 inhibitor 56 Alzhemed 56 Pancreas Cancer Vaccine 56 Phase II 56 ospemifene 56 CCR5 antagonist 56 orBec 56 LymphoStat B 56 SAR# [004] 56 ENDEAVOR IV 56 ColorectAlert TM 56 PORxin TM platforms 56 GLP toxicology 56 refractory CLL 56 Archexin 56 VA# [002] 56 denufosol 56 incyclinide 56 Cethrin 56 Trovax 56 OvaRex 56 oral prodrug 56 ozarelix 56 lorvotuzumab mertansine 56 pafuramidine 56 chemical entities NCEs 56 EpiCept NP 1 56 alemtuzumab MS 56 Riquent 56 ThermoDox R 56 Orazol 56 acyclovir Lauriad R 56 Intarcia 56 CYT# potent vascular disrupting 56 EDEMA3 56 Neo Kidney Augment 56 laninamivir 56 Veronate 56 maraviroc 56 Homspera 56 Varisolve 56 BAY #-# 56 candidates Dyloject TM 56 Zoraxel 56 UCB Cimzia 56 placebo controlled 56 Bexion 56 ADVEXIN clinical 56 pomalidomide 55 RELOVAIR ™ 55 LymphoStat B TM 55 Neuvenge 55 personalized dendritic cell 55 GRNVAC1 55 Viramidine 55 trials RCTs 55 rindopepimut 55 CELVAPAN H#N# 55 urocortin 2 55 Entereg 55 Torisel 55 Augment TM 55 Prodarsan 55 tezampanel NGX# 55 udenafil 55 Enobia 55 Puricase 55 Advagraf 55 albinterferon alfa 2b 55 Ozarelix 55 Stimuvax 55 Campath alemtuzumab 55 Reverset 55 Onco TCS 55 Japanese Encephalitis vaccine 55 Genasense ® 55 Gemin X 55 nalbuphine ER 55 lintuzumab 55 BETAS 55 aflibercept 55 telaprevir 55 Synavive 55 carcinogenicity study 55 MEK inhibitor 55 TRISENOX 55 APEX PD 55 Phase Ib IIa clinical 55 REOLYSIN ® 55 StaphVAX 55 TMC# [002] 55 vitro experiments 55 Valtropin 55 Phase #/#a trial 55 LCP AtorFen 55 Cancidas 55 lapatinib Tykerb 55 Affinitak 55 Vicinium TM 55 Itopride 55 solanezumab 55 ALGRX 55 Technosphere Insulin 55 Actilon 55 AIR inhaled insulin 55 superficial bladder cancer 55 bendamustine 55 Neuradiab 55 DermaVir Patch 55 carfilzomib 55 Puricase PEG uricase 55 Elocalcitol 55 Phase 1a clinical 55 Novolimus 55 Targretin 55 Ceplene 55 IMGN# 55 Octreolin 55 successfully commercialize Iluvien 55 phase III isavuconazole 55 balsalazide tablet 55 amrubicin 55 ELND# 55 PRX # 55 Tyrima 55 Relivar 55 abiraterone 55 Theratope 55 ustekinumab 55 Deferiprone 55 PROMACTA 55 ponatinib 55 myelofibrosis 55 TASKi3 55 TRO# 55 Cetrorelix 55 clazosentan 55 multicenter Phase III 55 human microdosing 55 hypoxia activated prodrug 55 StemEx 55 apaziquone 55 Nebido 55 VALOR trial 55 BioNumerik 55 Nuvion 55 PCA3 test 55 histone deacetylase HDAC inhibitor 55 lumiliximab 55 double blinded randomized 55 oral RSD# 55 clevidipine 55 dose escalation clinical 55 ORMD 55 Ceplene TM 55 Gabapentin GR 55 Glybera R 55 Plenaxis R 55 Cellegesic 55 Voraxaze 55 dose cohorts 55 Pafuramidine 55 EVIZON TM 55 Zytiga 55 DPX Survivac 55 ZoMaxx 55 efficacy tolerability 55 VEGF Trap 55 immunomodulatory therapy 55 Ostarine 55 maximally tolerated dose 55 TransMID 55 Arzerra ofatumumab 55 CR# vcMMAE 55 clofarabine 55 Cannabinor 55 NGX# 55 receptor tyrosine kinase inhibitor 55 PRTX 55 docetaxel Taxotere ® 55 Excellarate TM 55 molecular entities NMEs 55 postoperative ileus 55 immunological diseases 55 Iluvien ® 55 registrational studies 55 omecamtiv mecarbil 55 Phase III Trial 55 Lux Biosciences 55 recombinant factor VIIa 55 OMAPRO 55 mapatumumab 55 multicenter phase 55 Aerosurf 55 diarrhea predominant irritable 55 Certican 55 sunitinib malate 55 Afatinib 55 teplizumab 55 bevacizumab Avastin 55 aleglitazar 55 biologics 55 SRT# [003] 55 selective androgen receptor modulator 55 bosutinib 55 EndoTAG TM 55 ASCEND HF 55 ONCONASE R 55 Rhucin ® 55 Amplimexon 55 immatics 55 glatiramer acetate 55 ALN RSV# 55 Gattex 55 investigational compound 55 EGS# 55 TOCOSOL Camptothecin 55 PRECISE trial 55 synthetic retinoid 55 voclosporin 55 IIa trials 55 DCVax R 55 ACCLAIM trial 55 Zerenex 55 oral calcitonin 55 INT# [002] 55 Leukine 55 HepeX B 55 Actimmune ® 55 GAP #B# 55 CORLUX 55 TRANSDUR Sufentanil 55 IMC #B 55 Cerimon 55 Sular formulation 55 safinamide 55 EMPHASIS HF trial 55 Dapagliflozin 55 myoblast therapy 55 NexACT 55 IDX# 55 Aptivus 55 tofacitinib 55 Laquinimod 55 Surfaxin LS 55 LC#m# 55 diabetic neuropathic pain 55 dermaPACE TM 55 Zemplar Capsules 55 IPLEX 55 investigational antiplatelet agent 55 Ketotransdel 55 rNAPc2 55 CHAMPION PCI 55 FluCide 55 Microplasmin 55 STEDESA 55 immunotherapeutic vaccine 55 cetuximab Erbitux 55 Phase #b/#a clinical 55 perifosine 55 Onrigin 55 OFIRMEV 55 darapladib 55 Alocrest 55 NV1FGF 55 Genz # 55 velaglucerase alfa 55 Exelbine 55 HCV RESPOND 2 55 dimebon 55 SparVax TM 55 ISIS # 55 lenalidomide Revlimid R 55 Sym# 55 Annamycin 55 Phase III TRIST 55 Panzem R NCD 55 satraplatin 55 double blind placebo 55 VIAtab TM 55 iniparib 55 bortezomib Velcade 55 Phenserine 55 biologic 55 PROSTVAC ® 55 MGCD# [001] 55 ATIR TM 55 pralatrexate 55 rhC1INH 55 Marqibo 55 otelixizumab 55 Androxal TM 55 recombinant biopharmaceutical 55 Cloretazine R VNP#M 55 Aflibercept 55 sulodexide 55 Phase 1b clinical trials 55 SEBIVO 55 Ophena 55 galiximab 55 Fablyn 55 DAPT 55 NSABP 55 INS# [001] 55 Aviptadil 54 intravenous methylnaltrexone 54 bardoxolone methyl 54 Cx# [002] 54 MYCAMINE 54 RE LY 54 PD LID 54 IPLEX TM 54 Liprostin 54 AZD# TC 54 GEM OS2 54 Erbitux cetuximab 54 FavId 54 GeoVax vaccine 54 CLIRS trial 54 Loramyc R 54 Hycamtin 54 Entereg TM 54 Zometa zoledronic acid 54 Pivotal Phase III 54 fostamatinib 54 multiple ascending dose 54 Octreotide 54 Spiegelmer ® 54 cetrorelix 54 Celacade TM 54 Phase III VISTA 54 luliconazole 54 Poly ICR 54 Preos 54 tolerability 54 thorough QT 54 Fibrillex 54 paliperidone palmitate 54 CA4P 54 investigational hepatitis C 54 squalamine 54 Tolerx 54 midstage study 54 Aurexis 54 FACTIVE tablets 54 Novartis Zometa 54 dosing regimens 54 injectable collagenase 54 renal anemia 54 clinical endpoints 54 treatment naive genotype 54 tramiprosate 54 Xanafide 54 BRIM2 54 Pervasis 54 Removab 54 Navelbine ® 54 vitro studies 54 vorinostat 54 microbicide trials 54 II Clinical Trial 54 Fibrillex TM 54 MADIT II 54 ATL# [001] 54 AP# [003] 54 omacetaxine 54 MIST II 54 BioSTAR R 54 Prodarsan R 54 CRMD# 54 refractory Hodgkin lymphoma 54 acute decompensated heart 54 BARACLUDE R 54 unblinding 54 Ocrelizumab 54 Valdoxan 54 nalmefene 54 TKM PLK1 54 Virulizin ® 54 Specifid 54 Panzem R 54 Exelixis compounds 54 ONTAK 54 Milnacipran 54 Hectorol 54 RGB # 54 EGRIFTA TM 54 IMC A# 54 PFO migraine 54 randomized multicenter 54 voreloxin 54 tipranavir 54 SUVN 54 pharmacokinetic characteristics 54 SGS# 54 ALN PCS 54 Dynogen 54 Arcalyst 54 MDV# 54 Alinia 54 Daclizumab 54 AIR2 Trial 54 PREGNANT Study 54 huC# DM4 54 L DOS# 54 Ramoplanin 54 refractory gout 54 blinatumomab 54 UVIDEM 54 multicentre study 54 rimonabant Acomplia 54 QuatRx 54 randomized controlled clinical 54 PMA submission 54 Phase III Pivotal 54 randomized placebo controlled 54 XL# SAR# 54 custirsen 54 Quinamed 54 Tovaxin 54 AQUAVAN R 54 Allovectin 7 r 54 observational studies 54 Sutent 54 lasofoxifene 54 VNP#M 54 Neo Kidney Augment ™ 54 trials 54 Cloretazine R 54 glatiramer 54 omacetaxine mepesuccinate 54 Augment Bone Graft 54 RSD# 54 Oglemilast 54 orally dosed 54 Virulizin 54 oxymorphone ER 54 metastatic sarcomas 54 Aplidin 54 T Pred 54 sumatriptan DosePro 54 bio equivalence 54 edoxaban 54 QTinno TM 54 basal insulin analogue 54 PEG INTRON 54 novel VDA molecule 54 Mycograb 54 ascending dose 54 Interferon alpha 54 REMINYL ® 54 AVE# 54 interferon beta 1b 54 OMP #M# 54 prospective observational 54 Topical Interferon Alpha 2b 54 CytoFab ™ 54 gene therapy 54 IV metastatic melanoma 54 Ceflatonin 54 Azixa 54 Zebinix R 54 DU #b 54 Zingo TM 54 Tocosol Paclitaxel 54 PEP# [003] 54 Provenge prostate cancer 54 CBLC# 54 Zavesca 54 Inhalation Solution 54 ipilimumab 54 panitumumab 54 oral rivaroxaban 54 Inhaled insulin 54 OLYMPIA registry 54 vivo preclinical